[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100311460":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":10,"centralContacts":42,"locations":51,"responsibleParty":201,"collaborators":203,"id":209,"slug":10,"hasResults":210,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":10,"eligibilityCriteria":214,"healthyVolunteers":215,"sex":216,"minAge":217,"maxAge":10,"enrollmentInfo":218,"targetDuration":10,"studyType":221,"phases":10,"briefSummary":222,"conditions":223,"keywords":228,"overallStatus":54,"whyStopped":10,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":239},{"fullName":5,"class":6},"Memorial Sloan Kettering Cancer Center","OTHER",[8,15,19,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Locally Advanced or Metastatic Pancreatic Cancer Cohort",null,"For patients with locally advanced or metastatic PDAC, blood will be collected pre-treatment initiation (baseline), after first chemotherapy cycle, every 8-12 weeks while under treatment to coincide with restaging CT scan and at time of disease progression.",[13,14],"Diagnostic Test: Blood Draw","Diagnostic Test: Tumor Tissue Collection",{"label":16,"type":10,"description":17,"interventionNames":18},"Acute Benign Pancreatic Pathology Control Cohort","For patients with acute pancreatitis, blood specimens will be drawn at the time of acute pancreatitis and every 6-12 months thereafter",[13,14],{"label":20,"type":10,"description":21,"interventionNames":22},"Chronic Benign Pancreatic Path,IPMC & Pancreatic Cyst Ctrl","For patients with chronic pancreatitis, IPMN, or cysts, blood specimens will be drawn every 6-12 months.",[13,14,23],"Diagnostic Test: Cyst Fluid",{"label":25,"type":10,"description":26,"interventionNames":27},"Healthy Control","For normal controls, blood specimens will be drawn once at study baseline.",[13],[29,34,38],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":10},"DIAGNOSTIC_TEST","Blood Draw","If clinically safe, up to approximately 50ml of blood will be drawn, not to exceed the following criteria:\n\nPatients and controls weighing 50kg or more\n\n* For draw amounts up to 50mL, there is no required hemoglobin threshold.\n* For amounts exceeding 50mL, patients who meet standard blood banking criteria (e.g., hemoglobin values within normal limits and minimum weight of 50kg) may give as much as a full unit of blood (500mL) at one time or in divided fractions over a 56 day\u002Feight week period.\n\nPatients and controls weighing \\\u003C 50kg\n\n* For patients whose hemoglobin is below normal limits but at least 7.0 gm\u002FdL, no more than a total of 50 ml of blood or 5 ml\u002Fkg, whichever is less, may be collected per 56 day\u002Feight week period, but no more than approximately 2 ml\u002Fkg of blood at any one time.",[16,20,25,9],{"type":30,"name":35,"description":36,"armGroupLabels":37,"otherNames":10},"Tumor Tissue Collection","Tumor tissue will be obtained by already planned biopsy, either at Memorial Sloan Kettering Cancer Center or elsewhere",[16,20,9],{"type":30,"name":39,"description":40,"armGroupLabels":41,"otherNames":10},"Cyst Fluid","Cyst fluid will be obtained by already planned biopsy, either at Memorial Sloan Kettering Cancer Center or elsewhere",[20],[43,48],{"name":44,"role":45,"phone":46,"phoneExt":10,"email":47},"Kenneth Yu, MD","CONTACT","646-888-4188","yuk1@mskcc.org",{"name":49,"role":45,"phone":50,"phoneExt":10,"email":10},"David Kelson, MD","646-888-4179",[52,68,79,94,105,116,125,133,143,152,163,177,189],{"facility":53,"status":54,"city":55,"state":56,"zip":57,"country":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"Memorial Sloan Kettering Monmouth (All protocol activities)","RECRUITING","Middletown","New Jersey","07748","United States",{"type":60,"coordinates":61},"Point",[62,63],-74.11709,40.39428,{"lat":63,"lon":62},[66],{"name":67,"role":45,"phone":46,"phoneExt":10,"email":10},"Kenneth Yu, MD, M.Sc.",{"facility":69,"status":54,"city":70,"state":56,"zip":71,"country":58,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"Memorial Sloan Kettering Bergen (All protocol activities)","Montvale","07645",{"type":60,"coordinates":73},[74,75],-74.02292,41.04676,{"lat":75,"lon":74},[78],{"name":67,"role":45,"phone":46,"phoneExt":10,"email":10},{"facility":80,"status":81,"city":82,"state":83,"zip":84,"country":58,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"Cold Springs Harbor Laboratory (Specimen Analysis)","NOT_YET_RECRUITING","Cold Spring Harbor","New York","11724",{"type":60,"coordinates":86},[87,88],-73.45679,40.87149,{"lat":88,"lon":87},[91],{"name":92,"role":45,"phone":93,"phoneExt":10,"email":10},"David Tuveson, MD, PhD","516-367-5246",{"facility":95,"status":54,"city":96,"state":83,"zip":97,"country":58,"cosmosGeoPoint":98,"geoPoint":102,"contacts":103},"Memorial Sloan Kettering Cancer Center @ Commack (All Protocol Activities)","Commack","11725",{"type":60,"coordinates":99},[100,101],-73.29289,40.84288,{"lat":101,"lon":100},[104],{"name":67,"role":45,"phone":46,"phoneExt":10,"email":10},{"facility":106,"status":54,"city":107,"state":83,"zip":108,"country":58,"cosmosGeoPoint":109,"geoPoint":113,"contacts":114},"Memorial Sloan Kettering Westchester (All protocol activities)","Harrison","10604",{"type":60,"coordinates":110},[111,112],-73.71263,40.96899,{"lat":112,"lon":111},[115],{"name":67,"role":45,"phone":46,"phoneExt":10,"email":10},{"facility":117,"status":118,"city":83,"state":83,"zip":119,"country":58,"cosmosGeoPoint":120,"geoPoint":124,"contacts":10},"New York University","ACTIVE_NOT_RECRUITING","10010",{"type":60,"coordinates":121},[122,123],-74.00597,40.71427,{"lat":123,"lon":122},{"facility":126,"status":54,"city":83,"state":83,"zip":127,"country":58,"cosmosGeoPoint":128,"geoPoint":130,"contacts":131},"Memorial Sloan - Kettering Cancer Center","10021",{"type":60,"coordinates":129},[122,123],{"lat":123,"lon":122},[132],{"name":44,"role":45,"phone":46,"phoneExt":10,"email":10},{"facility":134,"status":54,"city":83,"state":83,"zip":135,"country":58,"cosmosGeoPoint":136,"geoPoint":138,"contacts":139},"Memorial Sloan Kettering Basking Ridge (All protocol activities)","10065",{"type":60,"coordinates":137},[122,123],{"lat":123,"lon":122},[140,141],{"name":67,"role":45,"phone":46,"phoneExt":10,"email":10},{"name":142,"role":45,"phone":10,"phoneExt":10,"email":10},"S",{"facility":144,"status":81,"city":83,"state":83,"zip":135,"country":58,"cosmosGeoPoint":145,"geoPoint":147,"contacts":148},"Weill Cornell Medical Center",{"type":60,"coordinates":146},[122,123],{"lat":123,"lon":122},[149],{"name":150,"role":45,"phone":151,"phoneExt":10,"email":10},"David Lyden, MD","212-746-6565",{"facility":153,"status":54,"city":154,"state":83,"zip":155,"country":58,"cosmosGeoPoint":156,"geoPoint":160,"contacts":161},"Memorial Sloan Kettering Nassau (All protocol activities)","Rockville Centre","11553",{"type":60,"coordinates":157},[158,159],-73.64124,40.65871,{"lat":159,"lon":158},[162],{"name":67,"role":45,"phone":46,"phoneExt":10,"email":10},{"facility":164,"status":81,"city":165,"state":10,"zip":166,"country":167,"cosmosGeoPoint":168,"geoPoint":172,"contacts":173},"Sha'are Zedek Medical Center","Jerusalem","91031","Israel",{"type":60,"coordinates":169},[170,171],35.21633,31.76904,{"lat":171,"lon":170},[174],{"name":175,"role":45,"phone":176,"phoneExt":10,"email":10},"Ephrat Levy-Lahad, PhD","646-497-2600",{"facility":178,"status":81,"city":179,"state":10,"zip":10,"country":167,"cosmosGeoPoint":180,"geoPoint":184,"contacts":185},"Weizmann Institute of Science","Rehovot",{"type":60,"coordinates":181},[182,183],34.81199,31.89421,{"lat":183,"lon":182},[186],{"name":187,"role":45,"phone":188,"phoneExt":10,"email":10},"Avigdor Scherz, PhD","972 8-934-2111",{"facility":190,"status":54,"city":191,"state":10,"zip":10,"country":167,"cosmosGeoPoint":192,"geoPoint":196,"contacts":197},"Sheba Medical Center","Tel Litwinsky",{"type":60,"coordinates":193},[194,195],34.84588,32.05096,{"lat":195,"lon":194},[198],{"name":199,"role":45,"phone":200,"phoneExt":10,"email":10},"Talia Golan, MD","03-5303295",{"type":202,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[204,206,208],{"name":190,"class":205},"OTHER_GOV",{"name":207,"class":6},"Weill Medical College of Cornell University",{"name":178,"class":6},"100311460",false,"NCT03334708","A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma","Development of Biomarkers for the Early Detection, Surveillance and Monitoring of Pancreatic Ductal Adenocarcinoma","Inclusion Criteria:\n\nCohort 1: Advanced Pancreatic Cancer Cohort Inclusion Criteria\n\n* Radiological, histological or cytological confirmed diagnosis of locally advanced or metastatic pancreatic adenocarcinoma by the enrolling institution\n* Patient planning to receive systemic treatment\n* Hemoglobin \\> 8\n* ECOG performance status 0-2\n* A minimum age of 18 years old\n* Willing to undergo a tumor biopsy\n* Willing to provide permission to obtain banked tumor tissue for analysis (previous biopsies or surgical material).\n\nCohort 2: Operable Pancreatic Cancer Cohort Inclusion Criteria\n\n* Radiological, histological or cytological confirmed diagnosis of pancreatic adenocarcinoma by the enrolling institution\n* Patient planned to undergo upfront resection\n* No pre-operative systemic therapy nor chemoradiation therapy planned\n* Hemoglobin \\> 8\n* ECOG performance status 0-2\n* A minimum age of 18 years old\n* Willing to undergo a tumor biopsy\n* Willing to provide permission to obtain banked tumor tissue for analysis (previous biopsies or surgical material).\n\nCohort 3: Acute Benign Pancreatic Pathology Control Inclusion Criteria\n\n* Confirmed diagnosis of acute pancreatitis or other acute pancreatic pathology by the enrolling institution\n* Hemoglobin \\> 8\n* ECOG performance status 0-2\n* A minimum age of 18 years old\n\nCohort 4: Chronic Benign Pancreatic Pathology Control Inclusion Criteria\n\n* Confirmed diagnosis of chronic pancreatitis or other non-cystic chronic pancreatic pathology by the enrolling institution\n* Hemoglobin \\> 8\n* ECOG performance status 0-2\n* A minimum age of 18 years old\n\nCohort 5: IPMN Control Inclusion Criteria\n\n* Confirmed diagnosis of IPMN without high risk features by the enrolling institution\n* A minimum age of 18 years old\n\nCohort 6: Pancreatic Cyst Control Inclusion Criteria\n\n* Confirmed diagnosis of benign pancreatic cyst by the enrolling institution\n* A minimum age of 18 years old\n\nCohort 7: Healthy Control Inclusion Criteria\n\n* A minimum age of 18 years old\n\nExclusion Criteria:\n\nCohort 1: Advanced Pancreatic Cancer Cohort Exclusion Criteria\n\n* Prior chemotherapy or radiation therapy for pancreatic cancer within the last 3 months in the localized setting\n* Active second malignancy, unless low grade malignancy\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures\n\nCohort 2: Operable Pancreatic Cancer Cohort Exclusion Criteria\n\n* Neoadjuvant chemotherapy or radiation therapy is planned\n* Active second malignancy, unless low grade malignancy\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures\n\nCohort 3: Acute Benign Pancreatic Pathology Control Exclusion Criteria\n\n* Active or prior malignancy, except prior non-melanoma skin cancer\n* Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures\n\nCohort 4: Chronic Benign Pancreatic Pathology Control Exclusion Criteria\n\n* Active or prior malignancy, except prior non-melanoma skin cancer\n* Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures\n\nCohort 5: IPMN Control Exclusion Criteria\n\n* IPMN with high risk features or planned resection\n* Active or prior malignancy, except prior non-melanoma skin cancer\n* Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures\n\nCohort 6: Pancreatic Cyst Control Exclusion Criteria\n\n* Active or prior malignancy, except prior non-melanoma skin cancer\n* Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures\n\nCohort 7: Healthy Control Exclusion Criteria\n\n* Active or prior malignancy, except prior non-melanoma skin cancer\n* Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures",true,"ALL","18 Years",{"count":219,"type":220},700,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to develop a minimally invasive test to diagnose pancreatic cancer at early stages of disease and monitor response to treatment.",[224,225,226,227],"Pancreatic Cancer","Pancreatic Diseases","Pancreatitis","Pancreatic Cyst",[229],"17-257","2025-12-01",{"date":232,"type":233},"2025-12-02","ACTUAL",{"date":235,"type":233},"2017-10-30",{"date":237,"type":220},"2026-10-30",{"name":5,"class":6},13]